Off-Label Use of Recombinant IGF-I to Promote Growth: Is It Appropriate?

摘要

The clinical rationale for such off-label promotion of mecasermin, however, has been challenged (3). The com- prehensive report by Midyett et al. (4) in the current issue of the Journal of Clinical Endocrinology and Metabolism provides important information about this approach. De- scribed is one year of treatment of children with idiopathic short stature (ISS) thought to have partial defects in GH sen- sitivity resulting in IGFD, based on a single measurement of circulating IGF-I less than —2 sp for chronological age.